3,500 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. purchased a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 3,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $595,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vestal Point Capital LP purchased a new position in shares of Jazz Pharmaceuticals in the second quarter valued at $127,344,000. Goldentree Asset Management LP purchased a new position in shares of Jazz Pharmaceuticals in the third quarter valued at $149,597,000. Schonfeld Strategic Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 592.1% in the third quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after purchasing an additional 373,383 shares during the period. AQR Capital Management LLC boosted its stake in shares of Jazz Pharmaceuticals by 62.1% in the second quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after purchasing an additional 304,463 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Jazz Pharmaceuticals by 11.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after purchasing an additional 298,815 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on JAZZ shares. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Royal Bank Of Canada raised their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Piper Sandler raised their target price on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, May 22nd. Weiss Ratings upgraded Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. Finally, Sanford C. Bernstein began coverage on Jazz Pharmaceuticals in a research note on Thursday, May 21st. They set a “market perform” rating and a $229.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $242.65.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks Research lifted near- and medium-term earnings forecasts for Jazz Pharmaceuticals, including FY2026 EPS to $21.72 from $18.70 and FY2027 EPS to $22.26 from $20.87, which suggests improving earnings power and supports a higher valuation.
• Positive Sentiment: Several quarterly estimates were also raised, including Q2 2026, Q3 2026, Q1 2027, Q3 2027, Q4 2027, and FY2028, reinforcing optimism around the company’s growth outlook.
• Positive Sentiment: The recent publication of Phase 3 HERIZON-GEA-01 results for Ziihera in The New England Journal of Medicine adds another potential catalyst by highlighting durable survival benefits in HER2+ gastroesophageal cancer. Article Title

Jazz Pharmaceuticals Trading Up 0.5%

JAZZ opened at $236.49 on Friday. The stock has a market capitalization of $14.84 billion, a PE ratio of -11,818.59, a P/E/G ratio of 0.41 and a beta of 0.27. The firm’s fifty day moving average price is $208.12 and its 200 day moving average price is $183.55. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. Jazz Pharmaceuticals PLC has a 12-month low of $105.00 and a 12-month high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 21.13 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Rick E. Winningham sold 2,741 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.57, for a total transaction of $662,143.37. Following the transaction, the director owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. This trade represents a 22.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the transaction, the director directly owned 384,682 shares in the company, valued at $73,281,921. The trade was a 1.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 12,028 shares of company stock worth $2,522,587. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.